Mr. Matthew J. D'Onofrio MBA
Co-Founder, CEO & Director
Biography unavailable
E
Evoke Pharma Inc
F:EV0
Evoke Pharma Inc
F:EV0
Price:
0.2036
EUR
-9.99%
Market Closed
Market Cap:
€680.6k
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
E
|
Evoke Pharma Inc
F:EV0
|
US |
|
Next PLC
LSE:NXT
|
UK |
|
B
|
Ball Corp
NYSE:BALL
|
US |
|
Bgc Group Inc
F:ESD
|
US |
|
Kusuri No Aoki Holdings Co Ltd
TSE:3549
|
JP |
|
S
|
Steakholder Foods Ltd
NASDAQ:STKH
|
IL |
|
X
|
Xilam Animation SA
F:XIH
|
FR |
|
Formula One Group
NASDAQ:FWONA
|
US |
|
K
|
K-Bro Linen Inc
OTC:KBRLF
|
CA |
|
A
|
Amdocs Ltd
F:AOS
|
GG |
|
LVMH Moet Hennessy Louis Vuitton SE
OTC:LVMHF
|
FR |
|
Curis Inc
NASDAQ:CRIS
|
US |
|
Ballard Power Systems Inc
TSX:BLDP
|
CA |
|
I
|
IES Holdings Inc
NASDAQ:IESC
|
US |
|
S
|
Sinopharm Group Co Ltd
OTC:SHTDY
|
CN |
Company Overview
Business Description
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Headquarters
- United States of America US
- Employees
- 4
- IPO date
- Sep 25, 2013
Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. The company is headquartered in Solana Beach, California and currently employs 4 full-time employees. The company went IPO on 2013-09-25. The firm is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. Evoke is developing its product Gimoti (metoclopramide) nasal spray for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Gimoti, is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a formulation of metoclopramide offering systemic delivery by nasal spray administration.